Schiff Counsels CNS Pharmaceuticals on $11.5M Public Offering
Schiff Hardin advised CNS Pharmaceuticals, Inc. in connection with its public offering of 5,750,000 shares of common stock and 2,875,000 warrants to purchase common stock for gross proceeds of $11.5 million.
Schiff Hardin advised CNS Pharmaceuticals, Inc. in connection with its public offering of 5,750,000 shares of common stock and 2,875,000 warrants to purchase common stock for gross proceeds of $11.5 million. The offering closed December 29, 2020.
CNS is biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. It intends to use the net proceeds from this offering for its Phase 2 trial for Berubicin, other research and development, and for working capital.
Smart In Your World
Your goals define our mission. Whether an immediate need or a long-term objective, ArentFox Schiff helps you reach your full potential. As industry insiders, we partner with you to develop practical business strategies and sophisticated legal solutions to achieve today’s targets and anticipate tomorrow’s problems. We get you across the finish line.
Contacts
-
Contact:
Nathan Carlile, Head of Firmwide Communications
- Related Industries
- Related Practices